News

Phase I clinical data of APIM’s lead compound ATX-101 will be presented at the 2021 ASCO Annual Meeting. The poster with the title: “A first-in-human (FIH) study of ATX-101, a drug targeting proliferating cell nuclear antigen (PCNA), shows a favorable safety profile and disease stabilization in late stage, heavily pre-treated, solid tumor patients” (abstract 3067), will be presented by Dr. Charlotte Lemech at the poster session “Developmental Therapeutics-Molecular Targeted Agents and Tumor Biology” on June 4 starting at 3:00 pm.

APIM Therapeutics was nominated as a top venture capital company in Norway by the Welp Magazine (#WelpMagazine). Please visit this link for more information.

Nucleic Acids Research publishes a study authored by NTNU Professor and APIM Therapeutics's CSO Marit Otterlei and co-workers. The study shows that peptides containing the PCNA interacting motif APIM bind to the β-clamp and inhibit bacterial growth and mutagenesis. These results suggest that APIM-peptides could have clinical applications in combination with other antibiotics and as single agents. A copy of the publication is available here.

Oncotarget publishes a study authored by APIM Therapeutics's CSO and NTNU Professor Marit Otterlei and co-workers. The paper focuses on non-canonical cytosolic roles of PCNA targeted by ATX-101, a cell-penetrating peptide containing the PCNA-interacting motif APIM. The results showed that ATX-101 increased the anti-cancer activity of EGFR/HER2/VEGFR inhibitors in vitro and in vivo. These results suggest that targeting the non-canonical roles of PCNA in cellular signaling with ATX-101 has the potential to improve the efficacy of targeted therapies. A copy of the publication is available here.

The International Journal of Molecular Sciences publishes a study authored by APIM Therapeutics's CSO and NTNU Professor Marit Otterlei and co-workers. The paper validates the APIM motif in the catalytic subunit of the essential mammalian TLS polymerase POLζ, REV3L. It further shows that ATX-101 reduces the mutation frequencies and changed the mutation spectra in several cell lines, suggesting that efficient TLS requires coordination mediated by interactions with PCNA. This has implication on the mutagenicity potential of multiple treatments in the presence of ATX-101. A copy of the publication is available here.

APIM Therapeutics announces regulatory approval of its clinical trial application recently submitted to Australian authorities. This approval will allow the company to initiate its planned multicenter, first-in-man phase I clinical trial evaluating the safety, tolerability and pharmacokinetics of ATX-101 in patients with advanced solid tumors. A copy of the relevant press release is available here.

Oncotarget publishes another important scientific paper authored by APIM Therapeutics's CSO and NTNU Professor Marit Otterlei and co-workers. The paper shows that ATX-101 improves the efficacy of cisplatin treatment in a rat model of Muscle Invasive Bladder Cancer (MIBC). ATX-101 also re-sensitizes cisplatin resistant bladder cells to the drug. The publication also presents mechanistic data from gene expression, proteome/kinome and metabolome studies. A copy of the publication is available here.

FEBS OPEN BIO publishes a study authored by APIM Therapeutics's CSO and NTNU Professor Marit Otterlei and co-workers. The paper shows that interactions of APIM‐containing signaling proteins and PCNA during the DNA damage response are evolutionary conserved between yeast and mammals and that PCNA has a role in cellular signaling also in yeast. A copy of the publication is available here.

APIM Therapeutics has submitted a formal application for clinical trial approval in Australia for ATX-101. The application will allow the company to initiate a multicenter, first-in-man phase I clinical trial evaluating the safety, tolerability and pharmacokinetics of ATX-101 in patients with advanced solid tumors. A copy of the relevant press release is available here.

Oncotarget publishes an important scientific paper authored by APIM Therapeutics's CSO and NTNU Professor Marit Otterlei and co-workers. The paper shows that ATX-101 improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer. A copy of the publication is available here.

APIM Therapeutics has announced that the company has closed a Financing round raising 25 mNOK (3 m$). Funds will be used to file a Clinical Trial Application (CTA) and start the clinical development program of APIM Therapeutics’ anti-cancer lead compound, ATX-101. A copy of the press release is available here.

APIM Therapeutics appoints Professor Justin Stebbing at its Advisory Board. Dr. Stebbing, a Professor of Cancer Medicine and Oncology, and a Consultant Oncologist at Imperial College and Imperial College Healthcare NHS Trust, is a world-renowned expert in clinical oncology with over 500 publications to his record. His expertise spans clinical practice as well as early and late stage trials of new drugs, mechanisms of disease and prognostic indicators.

APIM Therapeutics's CSO and NTNU Professor Marit Otterlei presents efficacy results obtained with ATX-101 in bladder and basal-like breast cancer models at the AACR Precision Medicine Series Conference: Targeting the Vulnerabilities of Cancer (Miami, May 16-19, 2016). A copy of the poster presented is available here.

APIM Therapeutics announced today that it has completed a new financing round by existing investors. This financing will enable the company to prepare for entry into first-in-man clinical studies within 2016.

APIM Therapeutics appoints Martin Welschof Ph.D to its Board of Directors. Martin, currently serving as the CEO of Opsona Therapeutics, adds significant development and commercialization expertise to the Board of APIM Therapeutics. For more information on Dr. Welschof's experience, please visit About Us.

UroToday.com Beyond the Abstract program publishes commentary by APIM Therapeutics's CSO Prof. Otterlei discussing the properties of PCNA targeting peptides such as ATX-101 to increase the anticancer efficacy of intravesical mitomycin-C therapy in bladder cancer. A copy of the commentary is available here.

APIM Therapeutics announced today that it has completed a new financing round by existing and new investors. This financing will enable the company to finalize preclinical development of ATX-101 aiming to file two clinical trial applications in late 2015 - early 2016.

Cell Signaling publishes an important scientific paper authored by APIM Therapeutics's CSO and NTNU Professor Marit Otterlei and co-workers. The paper describes a new platform/scaffold role of PCNA in the cytosol affecting key cellular signaling pathways such as the AKT, PI-3K and MAPK pathways. A pdf copy of the published article is available here.

Translational Oncology publishes an important scientific paper authored by APIM Therapeutics's CSO and NTNU Professor Marit Otterlei and co-workers. The paper presents proof-of-efficacy data of ATX-101 in two immuno-competent, orthotopic rat models of superficial bladder cancer in combination with Mitomycin-C. Results from this study corroborate the therapeutic potential of the company's technology. A pdf copy of the published article is available here.

APIM Therapeutics is featured with an 1-page article in European Biotechnology, a publication presenting key biotechnology companies active in Europe. A pdf copy of the published article is available here.